Phathom Pharmaceuticals (PHAT) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Phathom Pharmaceuticals (PHAT) has outperformed Valneva (VALN) over the past year, losing 37.2% versus a loss of 44.9%. Over five years, PHAT leads with a -79.1% price change compared with -79.1% for VALN. Valneva is the larger company by market cap ($556.6 million vs $550.9 million), about 1.0 times the size.
On valuation, Valneva trades at a lower forward P/E (4.9x vs 6.3x for Phathom Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAT | VALN |
|---|---|---|
| Share price | $6.81 | $5.87 |
| Market cap | $550.94M | $556.61M |
| 1-day change | +0.44% | +0.17% |
| YTD return | -58.95% | -33.45% |
| 1-year return | -37.18% | -44.88% |
| 5-year return | -79.05% | -79.07% |
| Forward P/E | 6.33 | 4.93 |
| EPS (TTM) | $-1.26 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.31 | $12.18 |
| 52-week low | $6.52 | $4.75 |
| Distance from 52-week high | -62.81% | -51.81% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +200.29% | +108.69% |
| Average volume | 1.39M | 77.94K |
| Shares outstanding | 80.90M | 94.82M |
| Employees | 371 | 620 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Healthcare · Biotechnology · 371 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Healthcare · Biotechnology · 620 employees
PHAT vs VALN FAQ
Which is bigger, Phathom Pharmaceuticals or Valneva?
Valneva (VALN) is larger, with a market capitalization of $556.61M compared with $550.94M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, PHAT or VALN?
PHAT returned -37.18% over the past 12 months, compared with -44.88% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Phathom Pharmaceuticals and Valneva in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.